chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient not feeling well after leaving office this morning. Sob, headache, cough and chills.   Patient is vaccinated and states that he feels like "death" advised to place covid testing in and patient reporting he would like to drive up in parking lot as he did 10 days prior.   Call and transfer to office to schedule.     Reason for Disposition ? [1] COVID-19 infection suspected by caller or triager AND [2] mild symptoms (cough, fever, or others) AND [3] no complications or SOB Answer Assessment - Initial Assessment Questions 3. ONSET: "When did the COVID-19 symptoms start?"      Today  4. WORST SYMPTOM: "What is your worst symptom?" (e.g., cough, fever, shortness of breath, muscle aches)     Cough, headache 5. COUGH: "Do you have a cough?" If so, ask: "How bad is the cough?"       moderate 6. FEVER: "Do you have a fever?" If so, ask: "What is your temperature, how was it measured, and when did it start?"     denies 7. RESPIRATORY STATUS: "Describe your breathing?" (e.g., shortness of breath, wheezing, unable to speak)      Asthma  9. HIGH RISK DISEASE: "Do you have any chronic medical problems?" (e.g., asthma, heart or lung disease, weak immune system, etc.)     Asthma  11. OTHER SYMPTOMS: "Do you have any other symptoms?"  (e.g., chills, fatigue, headache, loss of smell or taste, muscle pain, sore throat)       chills Protocols used: CORONAVIRUS (COVID-19) DIAGNOSED OR SUSPECTED-A-OH   ED  Discharged  10/21/2021 (2 hours) Treatment team COVID-19 Clinical impression Shortness of Breath ? Cough ? Fever  Patient presents with ? Shortness of Breath ? Cough ? Fever   ED Triage Vitals [10/21/21 1819] Temperature: (S) 37.6 °C (99.6 °F) Heart Rate: (!) 110 Resp: 20 BP: (!) 151/93 SpO2: 100 % Temp Source: Oral Heart Rate Source: Monitor Patient Position: Sitting BP Location: n/a FiO2 (%): n/a   History of Present Illness: 41-year-old male with Covid infection presents the emergency department with a variety of associated symptoms. The symptoms began 2 days ago. At that time he was also diagnosed with Covid. He tells me he has fatigue, myalgias and arthralgias, headache, nonproductive cough, shortness of breath, nausea and vomiting, diarrhea. He also notes abdominal pain that he attributes to frequent coughing. All symptoms are moderately intense, constantly present and getting neither better nor worse. He did speak to his doctor about getting monoclonal antibody infusion, this is in the process of being scheduled.
arm swelled up after dose 1; arm was red after dose 1; arm itched after dose 1; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (arm swelled up after dose 1), ERYTHEMA (arm was red after dose 1) and PRURITUS (arm itched after dose 1) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Thyroid disorder. Concomitant products included ALPRAZOLAM (XANAX) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (arm swelled up after dose 1), ERYTHEMA (arm was red after dose 1) and PRURITUS (arm itched after dose 1). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) at an unspecified dose and frequency. At the time of the report, PERIPHERAL SWELLING (arm swelled up after dose 1), ERYTHEMA (arm was red after dose 1) and PRURITUS (arm itched after dose 1) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medication includes: Medication for Blood pressure, Medication for Thyroid and water pill once in a while   This case was linked to MOD-2021-406413 (Patient Link).
Weakness, disproportionate fatigue, chest pain and tightness with exertion, shortness of breath with exertion. Unable to continue working retail job, dance for college dance classes, and photography due to symptom onset and worsening. Unable to participate in desired social activities due to weakness and fatigue. Can only walk short distances and not stand for long, because of symptoms. Tachycardia with minimal exertion such as walking and activities of daily living. Difficulty washing hair, folding clothes due to weakness and fatigue.
VERY PAINFUL BRIGHT RED SWOLLEN AREA 6-8" ALL AROUND INJECTION AREA, CHILLS, SWEATING, JOINT & MUSCLE PAIN, DEHYDRATION & NAUSEA FOR 3 DAYS.
Shingles/measles like rash on face. First spots appeared within about 24 hours of receiving the second shot and continued to spread for about one week.
Chronic, debilitating migraines since receiving vaccine in December and January Vaccines received on 12/16/20 and 1/6/21 Migraines began in January 2021 and have been unresponsive to multiple migraine medications. Currently under care of neurologist.
Acute pain to right shoulder and swelling.  Began 2 hours after injection. History of rheumatoid arthritis and bursitis. Demerol and Phenergan given for pain relief. Next day patient reported no relief for 24 hours following.
Fever of 99.6-104 F, shortness of breath, dizziness.
pt recvd vax;same day,has rash on back,lasted x 2 days;resolved w/out tx; 2nd dose given w/ no rxn;
Shaking all over, chills, fever, next morning felt fine - 11/8 at night was ok. Wednesday night 11/9/05, problems reoccurred similar problems on Thursday night couldn't get warm. Problems usually recurred at night. Today feels slightly warm and fatigued.
Approx. 2 months after injection, patient boticied a red welt on his arm where the vaccine was given. It is not painful but he reports that it is the size of a golfball.
Parent and tot in class in 1995-1996, noticed he was behind in speech and had an unsteady gait by the end of class. Tested in 1997 by private doctor and results PDD NOS.
This case was reported by a pharmacist via call center representative and described the occurrence of erythema of extremities in a 54-year-old female patient who received Shingrix (batch number ML532, expiry date unknown) for prophylaxis. On 13th August 2018, the patient received Shingrix (subcutaneous). On 13th August 2018, unknown after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. In August 2018, the patient experienced erythema of extremities, sweating, swelling arm and fever. On an unknown date, the outcome of the erythema of extremities, sweating, swelling arm and fever were not recovered/not resolved and the outcome of the intramuscular formulation administered by other route was unknown. It was unknown if the reporter considered the erythema of extremities, sweating, swelling arm and fever to be related to Shingrix. Additional details were provided as follows: The pharmacist reported that he administered Shingrix subcutaneously to a patient, which led to inappropriate route of vaccination. The patient's arm was red and swollen and it seemed to be spreading at the time of reporting.
Patient received a flu shot AFLURIA NDC 3332-0318-01 yesterday and after 4 hours she started to experience side effects and being diagnosed oculo-respiratory syndrome. She had pus came out of her eyes and red eyes. Hoarse, tight chest, fever, ache and chill.
PATIENT REPORTED AN IMMUNE RESPONSE OF FEVER OF 100 DEGREES FAHRENHEIT AND SWELLING AND RASH ON ARM VACCINE WAS GIVEN.
I had the vaccine at 12:23 PM and felt fine. At 2 am that same night I woke up sweating and my left side of my face was numb and tingling. I am able to move it but is continuing to tingle only on my left side. My lips, the very side of my tongue, my bottom jaw and my check bone constantly tingle and feel numb, when I talk some spit comes out on that side and my side of my nose also feels numb. As time goes on it isn't getting any better but not much worse. today my bottom lip just feels more numb
This spontaneous report was received from a healthcare worker and refers to a 9 months old patient of unknown gender. The patient's concurrent conditions, past medical history were not reported. On 16-DEC-2015, the patient was vaccinated with an improperly stored ROTATEQ (lot # K014826, expiry date 28-MAY-2016, dose, strength, vaccination site, dose number unspecified). Concomitant medications were not provided. No adverse effects were reported. Product quality complaint (PQC) was not reported. On 26-JAN-2016, a phone call was placed to the physician. The physician was unavailable at the time of call. The phone call was transferred to the Certified Medical Assistant (CMA). The C.M.A was unable to place specific lot numbers for each of the reported vaccines that experienced a temperature excursion; M-M-R II, ROTATEQ and VAQTA, with the information already supplied for patient identifiers, date of birth and date of vaccination, at this time. The C.M.A will need to review the records. This is one of the several reports received from the same reporter. Additional information has been requested.
A dose of PROQU AD was administered this morning 1/11/2021 and expired yesterday, 1/10/2021. The PROQUAD had never undergone a temperature excursion. No additional AE/no PQC.; A dose of PROQUAD was administered this morning 1/11/2021 and expired yesterday, 1/10/2021. The PROQUAD had never undergone a temperature excursion. No additional AE/no PQC.; This spontaneous report as received from a licensed practical nurse and refers to a patient of unknown age and gender.  No information about the patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions or allergies was provided.  On 11-JAN-2021, in the morning, the patient was vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) 0.5 milliliter once, for prophylaxis, lot # S021732, with expiration date of 10-JAN-2021 (expired product administered).  The measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) had never undergone a temperature excursion.  The patient did not experienced an adverse event.
sore left arm; Headache; dizziness; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Headache), DIZZINESS (dizziness) and PAIN IN EXTREMITY (sore left arm) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002b21a) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, the patient experienced HEADACHE (Headache) and DIZZINESS (dizziness). On 26-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore left arm). On 25-Mar-2021, HEADACHE (Headache) and DIZZINESS (dizziness) outcome was unknown. On 28-Mar-2021, PAIN IN EXTREMITY (sore left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Treatment medication was provided by the reporter. No concomitant medication was provided by the reporter. No lab data was provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2021-089330 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-089330:Husband Case
Vertigo upon laying in bed and turning my head.  Vertigo so bad in the am that I could not stand.
Patient presented to the pharmacy on 9/3 around 11am.  She presented with a hot, red rash on her upper left arm.  She had no fever, full range of motion.  She states the rash had not radiated elsewhere.  I drew a circle around the rash for her to reference and see if it were radiating.
Moderna COVID-19 Vaccine EUA dose given 38 days after BUD for refrigeration
Pt screamed for 5 hrs p/recvd initial dose of DTP/HIB 12MAR92;
Felt cold and could not get warm; Injection site area was warm to the touch; General side effects; Huge bright red circle around injection site; Injections site area did not hurt unless it was touched; Nausea; Headache; This spontaneous case was reported by a consumer and describes the occurrence of FEELING COLD (Felt cold and could not get warm), VACCINATION SITE WARMTH (Injection site area was warm to the touch), VACCINATION COMPLICATION (General side effects), VACCINATION SITE ERYTHEMA (Huge bright red circle around injection site) and VACCINATION SITE PAIN (Injections site area did not hurt unless it was touched) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, the patient experienced FEELING COLD (Felt cold and could not get warm), VACCINATION SITE WARMTH (Injection site area was warm to the touch), VACCINATION COMPLICATION (General side effects), VACCINATION SITE ERYTHEMA (Huge bright red circle around injection site), VACCINATION SITE PAIN (Injections site area did not hurt unless it was touched), NAUSEA (Nausea) and HEADACHE (Headache). In April 2021, FEELING COLD (Felt cold and could not get warm), VACCINATION SITE WARMTH (Injection site area was warm to the touch), VACCINATION COMPLICATION (General side effects), VACCINATION SITE ERYTHEMA (Huge bright red circle around injection site), VACCINATION SITE PAIN (Injections site area did not hurt unless it was touched), NAUSEA (Nausea) and HEADACHE (Headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication list was not provided. Treatment information was not provided.
Coughed so hard that dislocated my back; flu; Coughed; ruptured a disc; Initial information received on 26-Oct-2020 regarding an unsolicited valid serious case received from a consumer (patient) via social media.  This case was linked to cases 2020SA304086, 2020SA304087, 2020SA304088, 2020SA304089, 2020SA304084, 2020SA304082, 2020SA304083, 2020SA304085, 2020SA304090 and 2020SA304081 (same source).  This case involves a patient (unknown demographics) who experienced flu (influenza) and coughed (cough) so hard that it dislocated patient's back (dislocation of vertebra) and ruptured a disc (intervertebral disc protrusion), after patient received INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number and expiry date not reported via an unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed flu (influenza) 3 days following the administration of INFLUENZA VACCINE.  On an unknown date, the patient coughed (cough) so hard that it dislocated patient's back (dislocation of vertebra) and ruptured a disc (intervertebral disc protrusion) (unknown latency) following the administration of INFLUENZA VACCINE. Event dislocation of vertebra was assessed as medically significant.  Other relevant tests not reported.  It was not reported if the patient received a corrective treatment.  It was reported that now years later patient never had the flu but still suffer from the ruptured disc. Another flu shot and patient could be paralyzed for life.  At the time of reporting, the patient had not recovered from intervertebral disc protrusion and outcome was unknown for rest of the events.  There will be no information on the batch number for this case.; Sender's Comments: This poorly documented social media case concerns a patient (unknown demographics) who experienced influenza, cough, dislocation of vertebra and intervertebral disc protrusion after vaccination with INFLUENZA VACCINE (produced by unknown manufacturer). Time to onset was compatible for flu and unknown for rest of events. Also, patient's medical condition at the time of vaccination and lab tests ruling out alternate etiologies were not reported. Based upon the reported information, a causal role of the vaccine cannot be assessed.
SEVERE chills/shivering; significant nausea; tachycardia- mid to upper 120's; dizziness; fatique; headache; body aches; This is a spontaneous report from a contactable nurse (patient). This 50-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: Not available/provided to reporter at the time of report completion) via an unspecified route of administration on 21Dec2020 06:30 on right arm at a single dose for COVID-19 immunization. The patient no known allergy and no medical history. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications received within two weeks included methyprednisolone, azithromycin, celecoxib (CELEXA) and fish oil. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient has not been tested for COVID-19. The patient experienced severe chills/shivering, significant nausea, tachycardia- mid to upper 120's, dizziness, fatigue, headache, body aches on 21Dec2020 08:00. The patient received Zofran to treat nausea. The outcome of the events was recovering.  Information on Lot/Batch number has been requested.
Headache, Fatigue, light chills. taking Tynenol. it is improving slowly.
Transient episode of bilateral eyelid swelling. Onset 24 hours after vaccine administration, resolved 24 hours after onset spontaneously. Patient currently doing well, did not seek care.
FLU vaccine given yesterday (10/1/08) at approx 1540. Last night awoke crying with pain at injection site. Today thigh swollen from site to knee and buldase over knee. Slightly afebrile, able to walk without difficulty.
Psoriatic arthritis aggravated; Asthma; FACILITATED COLLECT  This is a Solicited report based on the information received by Pfizer from (Manufacturer Control No: 21K-163-3819448-00) from a non-contactable female consumer reporting for herself. This is the first of two reports.  A 66-year-old female subject received a dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), intramuscular on an unspecified date (Batch/Lot number was not reported) as single dose for COVID-19 immunisation; adalimumab (HUMIRA), subcutaneous from an unspecified date to an unspecified date (Batch/Lot number was not reported) at unspecified dose for an unspecified indication.  Medical history was none. No known allergies. There were no concomitant medications.  The subject experienced asthma and psoriatic arthritis aggravated, both on an unspecified date with outcome of unknown.  The action taken in response to the events for adalimumab was unknown. The reporter's causality for the event(s) of had COVID vaccine and had a really sore arm with HUMIRA (ADALIMUMAB) was no reasonable possibility. The reporter's causality for the events of COVID-19, psoriatic arthritis flare up and asthma was not provided.   The reporter's assessment of the causal relationship of the event with BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  The lot number for the vaccine, BNT162b2, was not provided and will be requested during follow up.; Sender's Comments: Based on the information provided, known drug safety profile and plausible temporal association, the causality between BNT162B2 and the events Psoriatic arthropathy and Asthma cannot be completely excluded. The impact of this report on the benefit-risk profile of the Pfizer product and on the conduct of the study is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, ethics committees. and investigators, as appropriate. ,Linked Report(s) : -PFIZER INC-202101241814 same patient, different event and dr
This spontaneous case was reported by a nurse and describes the occurrence of HEPATITIS C (Hep C) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Feb-2022, the patient experienced HEPATITIS C (Hep C) (seriousness criterion medically significant). The patient was treated with SOFOSBUVIR, VELPATASVIR (EPCLUSA) ongoing since an unknown date for Hepatitis C, at an unspecified dose and frequency. At the time of the report, HEPATITIS C (Hep C) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  Company comment: This spontaneous case report concerns a patient of an unknown age and gender with no medical history provided, who experienced serious (medically significant) unexpected event of Hepatitis C. According to the currently provided information, it is unclear whether the event occurred after the patient had received the third dose of the mRNA-1273 vaccine or Hepatitis C occurred prior to vaccination with mRNA-1273 vaccine. At the time of the reporting, the patient was treated with Epclusa for Hepatitis C infection and no additional details were available for medical assessment. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case report concerns a patient of an unknown age and gender with no medical history provided, who experienced serious (medically significant) unexpected event of Hepatitis C. According to the currently provided information, it is unclear whether the event occurred after the patient had received the third dose of the mRNA-1273 vaccine or Hepatitis C occurred prior to vaccination with mRNA-1273 vaccine. At the time of the reporting, the patient was treated with Epclusa for Hepatitis C infection and no additional details were available for medical assessment. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.
Soreness, lethargy/fatigue, and sneezing for approximately 3-4 days. Patient now feels completely fine.
DIZZY, WAVE OF HEAT, LIGHTS BLURRY, LESSER DEGREE THAN WITH MODERNA, WEAKNESS. BP 130/90, BS 134, 02 98%